Melissa McClenahan, PA
Physician Assistant · Meridian, IDNPI 1053695676
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 77.0% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $15,174, more than ten times the $216 reported in 2021. Among physician assistant clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $117.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$14K
- Boston Scientific$1K
- AbbVie$700
- Bayer$322
- Sumitomo Pharma America, Inc.$272
- Dendreon Pharmaceuticals LLC$226
- plus $2K from 24 others
What the payments were for
- Consulting fees$2501%
- Speaking & faculty fees$7,82042%
- Travel & lodging$6,66936%
- Food & beverage$3,71420%
- Education$1581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 33 | $14,324 |
| Boston Scientific | 9 | $1,248 |
| AbbVie(2 entities) | 20 | $700 |
| Bayer | 13 | $322 |
| Sumitomo Pharma America, Inc. | 11 | $272 |
| Dendreon Pharmaceuticals LLC | 9 | $226 |
| Pfizer | 7 | $206 |
| Astellas Pharma US Inc | 4 | $167 |
| Merck | 8 | $148 |
| Urogen Pharma, Inc. | 3 | $148 |
| Tolmar Pharmaceuticals, Inc. | 1 | $125 |
| Endo USA, Inc. | 5 | $98 |
| Accord Healthcare, Inc. | 6 | $96 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Olympus America Inc. | 3 | $47 |
| Sanofi | 2 | $46 |
| AstraZeneca | 3 | $44 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Bluewind Medical | 1 | $39 |
| Myovant Sciences Inc. | 2 | $32 |
| Laborie Medical Technologies Corp. | 1 | $29 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Novo Nordisk | 1 | $24 |
| Immunitybio, Inc. | 1 | $20 |
| Bioprotect Medical, Inc. | 1 | $19 |
| Telix Pharmaceuticals | 1 | $17 |
| Teleflex LLC | 1 | $15 |
| Urovant Sciences Inc | 1 | $13 |
| Travere Therapeutics, Inc. | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,611 in reported general payments places this provider in the 95th percentile of 1,027 physician assistant providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 210 | $138,544 |
| Abiraterone Acetate | 56 | $97,336 |
| OrgovyxRelugolix | 15 | $38,496 |
| Testosterone | 74 | $24,983 |
| GemtesaVibegron | 17 | $11,617 |
| Silodosin | 51 | $5,237 |
| Fosfomycin Tromethamine | 13 | $5,106 |
| Potassium Citrate ErPotassium Citrate | 27 | $4,893 |
| Solifenacin Succinate | 96 | $4,866 |
| Trospium Chloride | 54 | $3,711 |
| Tamsulosin Hcl | 276 | $2,200 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 77 | $1,674 |
| Methenamine Hippurate | 31 | $1,492 |
| Oxybutynin Chloride ErOxybutynin Chloride | 40 | $1,219 |
| Testosterone Cypionate | 18 | $1,187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $167 | $138,544210 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $272 | $50,11332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,027 physician assistant providers in Idaho.
Other physician assistant in Meridian
- Arthur NeaseMeridian$16K
- Alexander ArhetsMeridian$14K
- Jeremy FrixMeridian$12K
- David BarclayMeridian$11K
- Samuel ShinkleMeridian$10K
- Austin LeeMeridian$7K
- Teresa GraklanoffMeridian$7K
- Stephen FrellyMeridian$6K
- Rylan ChanMeridian$6K
- Brent TaylorMeridian$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.